Loading stock data…
USPH
$71.83+0.61 (+0.86%)
Market ClosedLast close May 1
U.S.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
U.S. Physical Therapy, Inc. in the Healthcare sector is trading at $71.83. The stock is currently near its 52-week low of $66.67, remaining 10.1% below its 200-day moving average. Technical signals show oversold RSI of 20 and bearish MACD signal, explaining why USPH maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 20) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$71.83
Potential Downside
63.5%
Whystock Fair Value$26.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$104.00+44.8%
Range$98.00 – $113.00
Fundamentals
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
53.18
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
240.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.00%
Volume
Today's trading volume
134,041
Recent News
PACS Group (PACS) Appoints Carey P. Hendrickson as Chief Financial Officer
PACS Group Inc. (NYSE:PACS) is one of the best up and coming stocks with highest upside potential. On April 27, PACS Group appointed Carey P. Hendrickson as its Chief Financial Officer. Hendrickson, a seasoned financial leader with nearly 40 years of experience, succeeds co-founder Mark Hancock, who had served as interim CFO since September 2025. […]
Is U.S. Physical Therapy, Inc. (USPH) A Good Stock To Buy Now?
Is USPH a good stock to buy? We came across a bullish thesis on U.S. Physical Therapy, Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on USPH. U.S. Physical Therapy, Inc.’s share was trading at $75.72 as of April 20th. USPH’s trailing and forward P/E were 53.32 and 27.03, respectively, according to Yahoo […]
3 Cash-Producing Stocks Walking a Fine Line
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +5.45% and +3.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How U.S. Physical Therapy’s New US$450 Million Credit Facilities Could Shape USPH Investors’ Outlook
On April 14, 2026, U.S. Physical Therapy, Inc. entered into a Fourth Amended and Restated Credit Agreement providing US$450,000,000 in senior credit facilities, including a US$275,000,000 revolving line and a US$175,000,000 term loan maturing in 2031. The expanded access to long-term credit, earmarked for refinancing existing borrowings and funding acquisitions and growth initiatives, reshapes the company’s financial flexibility and capacity to pursue its clinic and employer-health expansion...